Breaking the death spiral: Hal Barron talks about transforming the moribund R&D culture at GSK in a critical year for the late-stage pipeline
Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.
And that’s not easy, Barron is quick to note. He told the Financial Times:
I think that culture, to some extent, is as hard, in fact even harder, than doing the science.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.